Bukwang Pharmaceutical Co., Ltd. Statistics
Want to see KR:003000 full AI Analyst Report?
Bukwang Pharmaceutical Co., Ltd. (003000) Stock Statistics & Valuation Metrics
Total Valuation
Bukwang Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 393.18B. The enterprise value is KRW 334.11B.
- Market Cap
- KRW 393.18B
- Enterprise Value
- KRW 334.11B
Share Statistics
Bukwang Pharmaceutical Co., Ltd. has 98,664,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 98,664,670
- Owned by Insiders
- ―
- Owned by Institutions
- 5.02%
Financial Efficiency
Bukwang Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.05%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 3.05%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 308.79M
- Profits Per Employee
- 19.34M
- Employee Count
- 650
- Asset Turnover
- 0.40
- Inventory Turnover
- 2.01
Valuation Ratios
The current PE Ratio of Bukwang Pharmaceutical Co., Ltd. is 68.96. Bukwang Pharmaceutical Co., Ltd.’s PEG ratio is -1.23.
- PE Ratio
- 68.96
- PS Ratio
- 1.75
- PB Ratio
- 1.20
- Price to FCF
- -88.36
- Price to Operating Cash Flow
- 118.13
- PEG Ratio
- -1.23
Income Statement
In the last 12 months, Bukwang Pharmaceutical Co., Ltd. had revenue of 200.71B and earned 12.57B in profits. Earnings per share was 152.00.
- Revenue
- 200.71B
- Gross Profit
- 95.72B
- Operating Income
- 14.16B
- Pretax Income
- 6.39B
- Net Income
- 12.57B
- EBITDA
- 19.65B
- Earnings Per Share (EPS)
- 152.00
Cash Flow
In the last 12 months, operating cash flow was 3.39B and capital expenditures -7.84B, giving a free cash flow of -4.45B billion.
- Operating Cash Flow
- 3.39B
- Free Cash Flow
- -4.45B
- Free Cash Flow per Share
- -44.30
Dividends & Yields
Bukwang Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 3.14%
- Dividend Per Share
- ―
- Dividend Yield
- 3.14%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.13%
- Earnings Yield
- 2.05%
Stock Price Statistics
- Beta
- 0.04
- 52-Week Price Change
- 0.63%
- 50-Day Moving Average
- 3932.10
- 200-Day Moving Average
- 4943.32
- Relative Strength Index (RSI)
- 55.08
- Average Volume (3m)
- 412.90K
Important Dates
Bukwang Pharmaceutical Co., Ltd. upcoming earnings date is Mar 22, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 23, 2026
- Next Earnings Date
- Mar 22, 2027
- Ex-Dividend Date
- ―
Financial Position
Bukwang Pharmaceutical Co., Ltd. as a current ratio of 2.59, with Debt / Equity ratio of 23.53%
- Current Ratio
- 2.59
- Quick Ratio
- 2.15
- Debt to Market Cap
- 0.21
- Net Debt to EBITDA
- 2.09
- Interest Coverage Ratio
- 3.63
Taxes
In the past 12 months, Bukwang Pharmaceutical Co., Ltd. has paid -6.05B in taxes.
- Income Tax
- -6.05B
- Effective Tax Rate
- -0.95
Enterprise Valuation
Bukwang Pharmaceutical Co., Ltd. EV to EBITDA ratio is 22.38, with an EV/FCF ratio of -83.09.
- EV to Sales
- 1.64
- EV to EBITDA
- 22.38
- EV to Free Cash Flow
- -83.09
- EV to Operating Cash Flow
- 109.13
Balance Sheet
Bukwang Pharmaceutical Co., Ltd. has KRW 169.10B in cash and marketable securities with KRW 80.67B in debt, giving a net cash position of KRW 88.43B billion.
- Cash & Marketable Securities
- KRW 169.10B
- Total Debt
- KRW 80.67B
- Net Cash
- KRW 88.43B
- Net Cash Per Share
- KRW 896.25
- Tangible Book Value Per Share
- KRW 3,356.03
Margins
Gross margin is 35.18%, with operating margin of 5.69%, and net profit margin of 3.65%.
- Gross Margin
- 35.18%
- Operating Margin
- 5.69%
- Pretax Margin
- 3.98%
- Net Profit Margin
- 3.65%
- EBITDA Margin
- 7.33%
- EBIT Margin
- 5.69%
Analyst Forecast
The average price target for Bukwang Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 22.17%
- EPS Growth Forecast
- -38.54%
Scores
- Smart Score
- ―
- AI Score
- 50

